Reply to: Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.

Autor:	Brookes MJ; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; North of England Bone and Soft Tissue Tumour Service, Royal Victoria Infirmary, Newcastle upon Tyne, UK., Roundhill EA; Children's Cancer Research Group, Leeds Institute of Medical Research, St. James's University Hospital, Leeds, UK., Jeys L; Royal Orthopaedic Hospital NHS Foundation Trust, Northfield, Birmingham, UK., Parry M; Royal Orthopaedic Hospital NHS Foundation Trust, Northfield, Birmingham, UK., Burchill SA; Children's Cancer Research Group, Leeds Institute of Medical Research, St. James's University Hospital, Leeds, UK., Rankin KS; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.; North of England Bone and Soft Tissue Tumour Service, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Jazyk:	angličtina
Zdroj:	Pediatric blood & cancer [Pediatr Blood Cancer] 2023 May; Vol. 70 (5), pp. e30206. Date of Electronic Publication: 2023 Jan 18.
DOI:	10.1002/pbc.30206
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text